Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions

CAR-T Digest - August 2020

Weekly Digest - June 2026

01 June 2026: Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions advanced Solid tumor study

Mabion and KriSan Biotech have signed a Letter of Intent (LOI) to explore a strategic collaboration in antibody-drug conjugates (ADCs), bringing together complementary expertise to address the growing global demand for ADC development and manufacturing services
The proposed partnership aims to combine Mabion’s capabilities in biologics development, advanced analytics, and GMP manufacturing with KriSan Biotech’s specialized expertise in linker-payload technologies, conjugation processes, and ADC-related manufacturing services
Through the collaboration, the companies intend to explore an integrated end-to-end service offering spanning antibody development, analytical characterization, conjugation, and GMP production, enabling support for increasingly complex ADC programs
The partnership is expected to create new business development opportunities across Europe and Asia, leveraging the companies’ complementary geographic footprints and technical capabilities to provide coordinated commercial proposals and joint execution of ADC-related client projects
Strategically, the LOI supports Mabion’s broader ambition to expand beyond traditional biologics manufacturing into high-value ADC services, while strengthening its presence in the Asian market and positioning both companies to capitalize on the rapidly growing global ADC outsourcing and CDMO landscape